Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

PLoS Medicine

Volumn 3, Issue 12, 2006, Pages 2264-2273

  Lee, Jeffrey C ^a,b   Vivanco, Igor ^c   Beroukhim, Rameen ^a,b   Huang, Julie H Y ^c   Feng, Whei L ^a,b   DeBiasi, Ralph M ^a,b   Yoshimoto, Koji ^c   King, Jennifer C ^c   Nghiemphu, Phioanh ^c   Yuza, Yuki ^a   Xu, Qing ^a   Greulich, Heidi ^a,b   Thomas, Roman K ^a,b   Paez, J Guillermo ^a,b   Peck, Timothy C ^a,b   Linhart, David J ^a,b   Glatt, Karen A ^a   Getz, Gad ^b   Onofrio, Robert ^b   Ziaugra, Liuda ^b   Levine, Ross L ^a,d   Gabriel, Stacey ^b   Kawaguchi, Tomohiro ^e   O'Neill, Keith ^b   Khan, Haumith ^c   Liau, Linda M ^c   Nelson, Stanley F ^c   Rao, P Nagesh ^c   Mischel, Paul ^c   Pieper, Russell O ^e   Cloughesy, Tim ^c   Leahy, Daniel J ^f   Sellers, William R ^a,b   Sawyers, Charles L ^c,g   Meyerson, Matthew ^a,b   Mellinghoff, Ingo K ^c   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; LIGAND; MUTANT PROTEIN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ALLELE; AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CARCINOGENICITY; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG SENSITIVITY; EXTRACELLULAR SPACE; GENE CLUSTER; GENE DOSAGE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; MISSENSE MUTATION; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE; ANIMAL; ASTROCYTE; BINDING SITE; CELL CULTURE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ASTROCYTES; BINDING SITES; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; MODELS, MOLECULAR; MUTATION, MISSENSE; NEOPLASMS, EXPERIMENTAL; NIH 3T3 CELLS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 33845926387     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030485     Document Type: Article

References (46)

1. Hynes NE, Lane HA (2005) ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
2. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, et al. (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215-225; discussion 226-219.
3. Reardon DA, Rich JN, Friedman HS, Bigner DD (2006) Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24: 1253-1265.
4. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, et al. (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313: 144-147.
5. Yamazaki H, Fukui Y, Ueyama Y, Tamaoki N, Kawamoto T, et al. (1988) Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol Cell Biol 8: 1816-1820.
6. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, et al. (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89: 2965-2969.
7. Ekstrand AJ, Sugawa N, James CD, Collins VP (1992) Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or Cterminal tails. Proc Natl Acad Sci U S A 89: 4309-4313.
8. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, et al. (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97: 880-887.
9. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012-2024.
10. Ross P, Hall L, Smirnov I, Haff L (1998) High level multiplex genotyping by MALDI-TOF mass spectrometry. Nat Biotechnol 16: 1347-1351.
11. Li C, Wong WH (2001) Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc Natl Acad Sci U S A 98: 31-36.
12. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E (2004) Analysis of array CGH data: From signal ratio to gain and loss of DNA regions. Bioinformatics 20: 3413-3422.
13. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, et al. (2005) Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2: e313. doi:10.1371/journal.pmed.0020313
14. Riese DJ 2nd, van Raaij TM, Plowman GD, Andrews GC, Stern DF (1995) The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol 15: 5770-5776.
15. Palacios R, Steinmetz M (1985) Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41: 727-734.
16. Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, et al. (2001) Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res 61: 4956-4960.
17. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
18. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
19. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
20. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE (2004) Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 351: 2883.
21. Rich JN, Rasheed BK, Yan H (2004) EGFR mutations and sensitivity to gefitinib. N Engl J Med 351: 1260-1261 author reply 1260-1261.
22. Marie Y, Carpentier AF, Omuro AM, Sanson M, Thillet J, et al. (2005) EGFR tyrosine kinase domain mutations in human gliomas. Neurology 64: 1444-1445.
23. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
24. Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60: 1383-1387.
25. Velu TJ, Beguinot L, Vass WC, Willingham MC, Merlino GT, et al. (1987) Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science 238: 1408-1410.
26. Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, et al. (1987) Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51: 1063-1070.
27. Wiley HS (2003) Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res 284: 78-88.
28. Pierce JH, Ruggiero M, Fleming TP, Di Fiore PP, Greenberger JS, et al. (1988) Signal transduction through the EGF receptor transfected in IL-3-dependent hematopoietic cells. Science 239: 628-631.
29. Collins MK, Downward J, Miyajima A, Maruyama K, Arai K, et al. (1988) Transfer of functional EGF receptors to an IL3-dependent cell line. J Cell Physiol 137: 293-298.
30. Walker F, Hibbs ML, Zhang HH, Gonez LJ, Burgess AW (1998) Biochemical characterization of mutant EGF receptors expressed in the hemopoietic cell line BaF/3. Growth Factors 16: 53-67.
31. Yang S, Qu S, Perez-Tores M, Sawai A, Rosen N, et al. (2006) Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res 66: 6990-6997.
32. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, et al. (2003) PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 3: 459-469.
33. Shah NP, Tran C, Lee FY, Chen P, Norris D, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.
34. Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, et al. (2005) Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106: 721-724.
35. Jiang J, Greulich H, Janne PA, Sellers WR, Meyerson M, et al. (2005) Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 65: 8968-8974.
36. Daley GQ, Baltimore D (1988) Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A 85: 9312-9316.
37. Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445-2459.
38. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
39. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
40. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, et al. (2003) Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300: 949.
41. Rand V, Huang J, Stockwell T, Ferriera S, Buzko O, et al. (2005) Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A 102: 14344-14349.
42. Arjona D, Bello MJ, Alonso ME, Aminoso C, Isla A, et al. (2005) Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations. Neuropathol Appl Neurobiol 31: 384-394.
43. Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, et al. (2005) An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 65: 7096-7101.
44. Sawyers CL (2005) Calculated resistance in cancer. Nat Med 11: 824-825.
45. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, et al. (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 91: 7727-7731.
46. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, et al. (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7: 301-311.